Protocol Outlines for Parts 1 and 2 of the Prospective Endoscopy III Study for the Early Detection of Colorectal Cancer: Validation of a Concept Based on Blood Biomarkers

Louise Rasmussen, Michael Wilhelmsen, Ib Jarle Christensen, Jens Andersen, Lars Nannestad Jørgensen, Morten Rasmussen, Jakob W Hendel, Mogens R Madsen, Jesper Vilandt, Thore Hillig, Michael Klærke, Anna-Marie Bloch Münster, Lars M Andersen, Berit Andersen, Nete Hornung, Erland J Erlandsen, Ali Khalid, Hans Jørgen Nielsen, Louise Rasmussen, Michael Wilhelmsen, Ib Jarle Christensen, Jens Andersen, Lars Nannestad Jørgensen, Morten Rasmussen, Jakob W Hendel, Mogens R Madsen, Jesper Vilandt, Thore Hillig, Michael Klærke, Anna-Marie Bloch Münster, Lars M Andersen, Berit Andersen, Nete Hornung, Erland J Erlandsen, Ali Khalid, Hans Jørgen Nielsen

Abstract

Background: Programs for population screening of colorectal cancer (CRC) have been implemented in several countries with fecal immunochemical testing (FIT) as the preferred platform. However, the major obstacle for a feces-based testing method is the limited compliance that reduces the clinical sensitivity for detection of participants with non-symptomatic CRC. Therefore, research approaches have been initiated to develop screening concepts based on biomarkers in blood. Preliminary results show that protein, genetic, epigenetic, and metabolomic components may be valuable in blood-based screening concepts, particularly when combinations of the various components appear to lead to significant improvements.

Objectives: The protocol described in this paper focuses on the validation of concepts based on biomarkers in blood in a major population screened by FIT.

Methods: In Part 1, participants will be identified and included through the Danish CRC Screening Program comprising initial FIT and subsequent colonoscopy to those with a positive result. Blood samples will be collected from 8000 FIT-positive participants, who are offered subsequent colonoscopy. Findings and interventions at colonoscopy together with personal data including co-morbidity will be recorded. Blood samples and data will also be collected from 6000 arbitrarily chosen participants with negative FIT. In Part 2, blood samples and data will be collected from 30,000 FIT-negative participants three times within 4 years. The blood samples will be analyzed using various in-house and commercially available manual and automated analysis platforms.

Results: We anticipate Part 1 to terminate late August 2016 and Part 2 to terminate late September 2022. The results from Parts 1 and 2 will be presented within 12 to 18 months from termination.

Conclusions: The purpose of this study is to improve the efficacy of identifying participants with neoplastic bowel lesions, to identify false negative participants, to identify participants at risk of interval neoplastic lesions, to improve the compliance in screening sessions, and to establish guidelines for out-patient follow-up of at-risk participants based on combinations of blood-based biomarkers.

Keywords: colorectal neoplasms; early detection of cancer; epigenomics; genomics; metabolomics; proteomics; transcriptome.

Conflict of interest statement

Conflicts of Interest: None declared.

References

    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374–403. doi: 10.1016/j.ejca.2012.12.027.
    1. Aziz N, Rowland J. Trends and advances in cancer survivorship research: challenge and opportunity. Semin Radiat Oncol. 2003 Jul;13(3):248–66. doi: 10.1016/S1053-4296(03)00024-9.
    1. Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology. 2014 Mar;146(3):709–17. doi: 10.1053/j.gastro.2013.09.001.
    1. Lindebjerg J, Osler M, Bisgaard C. Colorectal cancers detected through screening are associated with lower stages and improved survival. Dan Med J. 2014 Jan;61(1):A4758.
    1. Garborg K, Holme Ø, Løberg M, Kalager M, Adami HO, Bretthauer M. Current status of screening for colorectal cancer. Ann Oncol. 2013 Aug;24(8):1963–72. doi: 10.1093/annonc/mdt157.
    1. Faivre J, Dancourt V, Lejeune C. Screening for colorectal cancer with immunochemical faecal occult blood tests. Dig Liver Dis. 2012 Dec;44(12):967–73. doi: 10.1016/j.dld.2012.07.004.
    1. Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer. 2013 Sep;49(14):3049–54. doi: 10.1016/j.ejca.2013.04.023.
    1. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008 Jul;135(1):82–90. doi: 10.1053/j.gastro.2008.03.040.
    1. Parente F, Boemo C, Ardizzoia A, Costa M, Carzaniga P, Ilardo A, Moretti R, Cremaschini M, Parente EM, Pirola ME. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy. Endoscopy. 2013;45(1):27–34. doi: 10.1055/s-0032-1325800.
    1. Klabunde C, Blom J, Bulliard J, Garcia M, Hagoel L, Mai V, Patnick J, Rozjabek H, Senore C, Törnberg S. Participation rates for organized colorectal cancer screening programmes: an international comparison. J Med Screen. 2015 Sep;22(3):119–26. doi: 10.1177/0969141315584694.
    1. Taber JM, Aspinwall LG, Heichman KA, Kinney AY. Preferences for blood-based colon cancer screening differ by race/ethnicity. Am J Health Behav. 2014 May;38(3):351–61. doi: 10.5993/AJHB.38.3.4.
    1. Adler A, Geiger S, Keil A, Bias H, Schatz P, deVos T, Dhein J, Zimmermann M, Tauber R, Wiedenmann B. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014;14:183. doi: 10.1186/1471-230X-14-183.
    1. Nielsen HJ, Brünner N, Jorgensen LN, Olsen J, Rahr HB, Thygesen K, Hoyer U, Laurberg S, Stieber P, Blankenstein MA, Davis G, Dowell BL, Christensen IJ, Danish Endoscopy Study Group on Colorectal Cancer Detection. Danish Colorectal Cancer Cooperative Group Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol. 2011 Jan;46(1):60–9. doi: 10.3109/00365521.2010.513060.
    1. Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, von PJ, Raith H, Feldmann K, Kremer AE, Müller S, Geiger S, Hamann GF, Seidel D, Stieber P. Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci. 2008 Aug;1137:180–9. doi: 10.1196/annals.1448.012.
    1. Kharaziha P, Ceder S, Li Q, Panaretakis T. Tumor cell-derived exosomes: a message in a bottle. Biochim Biophys Acta. 2012 Aug;1826(1):103–11. doi: 10.1016/j.bbcan.2012.03.006.
    1. Luo X, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS One. 2013;8(5):e62880. doi: 10.1371/journal.pone.0062880.
    1. Nielsen HJ, Jakobsen KV, Christensen IJ, Brünner N, Danish Study Group on Early Detection of Colorectal Cancer Screening for colorectal cancer: possible improvements by risk assessment evaluation? Scand J Gastroenterol. 2011 Nov;46(11):1283–94. doi: 10.3109/00365521.2011.610002.
    1. Mouliere F, Thierry AR. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. Expert Opin Biol Ther. 2012 Jun;12 Suppl 1:S209–15. doi: 10.1517/14712598.2012.688023.
    1. Thorsen SB, Lundberg M, Villablanca A, Christensen SL, Belling KC, Nielsen BS, Knowles M, Gee N, Nielsen HJ, Brünner N, Christensen IJ, Fredriksson S, Stenvang J, Assarsson E. Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals. J Transl Med. 2013;11:253. doi: 10.1186/1479-5876-11-253.
    1. Bro R, Nielsen HJ, Savorani F, Kjeldahl K, Christensen IJ, Brünner N, Lawaetz AJ. Data fusion in metabolomic cancer diagnostics. Metabolomics. 2013 Feb;9(1):3–8. doi: 10.1007/s11306-012-0446-0.
    1. Wang J, Huang S, Zhao M, Yang M, Zhong J, Gu Y, Peng H, Che Y, Huang C. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One. 2014;9(4):e87451. doi: 10.1371/journal.pone.0087451.
    1. Symonds EL, Pedersen S, Cole SR, Massolino J, Byrne D, Guy J, Backhouse P, Fraser RJ, LaPointe L, Young GP. Improving participation in colorectal cancer screening: a randomised controlled trial of sequential offers of faecal then blood based non-invasive tests. Asian Pac J Cancer Prev. 2015;16(18):8455–60.
    1. Kring TS, Piper TB, Jørgensen LN, Olsen J, Rahr HB, Nielsen KT, Laurberg S, Davis G, Dowell B, Johansen JS, Christensen IJ, Brünner N, Nielsen HJ. Blood-based biomarkers at large bowel endoscopy and prediction of future malignancies. Biomark Cancer. 2015;7:57–61. doi: 10.4137/BIC.S31330.
    1. Blume J, Wilhelmsen M, Benz R, Brünner N, Christensen I, Croner L. Discovery and validation of plasma-protein biomarker panels for the detection of colorectal cancer and advanced adenoma in a Danish collection of samples from subjects referred for diagnostic colonoscopy. J Appl Lab Med. 2016 Aug 23;
    1. Tian L, Tibshirani R. Adaptive index models for marker-based risk stratification. Biostatistics. 2011 Jan;12(1):68–86. doi: 10.1093/biostatistics/kxq047.
    1. Lochhead P, Chan AT, Giovannucci E, Fuchs CS, Wu K, Nishihara R, O'Brien M, Ogino S. Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol. 2014 Aug;109(8):1205–14. doi: 10.1038/ajg.2014.153.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel